Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the breast that is potentially curable~  * T0-4 (dermal involvement on pathology assessment only), N0-2, M0~ * No clinical T4 disease~* Previously treated with one of the following:~  * Total mastectomy and level II axillary node dissection~ * Partial mastectomy and level II axillary node dissection with planned breast radiotherapy after completion of adjuvant chemotherapy regimen\*~ * Patients with a positive sentinel node biopsy must undergo level II axillary node dissection or sufficient nodal sampling~ * If microscopic residual in situ or invasive disease is present at total or partial mastectomy margins, planned radiotherapy must also include a boost to the tumor bed~* No residual tumor in the axilla after dissection~* Axillary node positive~  * Negative nodes allowed if the tumor is ≥ 1 cm and 1 or more of the following criteria defining high-risk node-negative disease are met:~    * Histological grade III or,~   * Estrogen receptor negative or,~   * Lymphatic/vascular invasion~* Hormone receptor status:~  * Estrogen receptor status known~PATIENT CHARACTERISTICS:~Age:~* 60 and under~Sex:~* Female~Menopausal status:~* Pre- or postmenopausal~Performance status:~* ECOG 0-2~Life expectancy:~* At least 5 years~Hematopoietic:~* WBC ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic:~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~Renal:~* Creatinine ≤ 1.5 times ULN~Cardiovascular:~* LVEF ≥ limit of normal by MUGA or echocardiogram~* No arrhythmia requiring ongoing treatment~* No congestive heart failure~* No documented coronary artery disease~Other:~* No other malignancy except:~  * Adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~ * Ductal or lobular carcinoma in situ that has been curatively treated by surgery alone~ * Other prior malignancies (except breast cancer) curatively treated more than 5 years prior to study entry~* No serious underlying medical illness or psychiatric or addictive disorder that would preclude study compliance~* No known hypersensitivity to E. coli-derived products, mammalian-cell derived products, or any study agents~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective non-hormonal contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for breast cancer~* No concurrent pegfilgrastim or darbepoetin alfa (Arm II)~  * Allowed on arms 1 and 3 if medically necessary~Chemotherapy:~* No prior chemotherapy for breast cancer~Endocrine therapy:~* No prior hormonal therapy for breast cancer~* No concurrent hormone replacement therapy~* No concurrent selective estrogen-receptor modulators (e.g., raloxifene for the treatment or prevention of osteoporosis)~* No concurrent oral contraceptives (i.e., birth control pills)~* No other concurrent aromatase inhibitors~Radiotherapy:~* See Disease Characteristics~* No prior radiotherapy for breast cancer~Surgery:~* See Disease Characteristics~* No more than 12 weeks since prior total or partial mastectomy (including re-excision of margins)~Other:~* At least 30 days since prior investigational drugs~* No other concurrent investigational drugs~* Concurrent bisphosphonates for the treatment or prevention of osteoporosis allowed

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: CEF (Type: ACTIVE_COMPARATOR): 6 cycles - q 28 days (6 months) - Cyclophosphamide 75 mg/m2 - po - Days 1-14 - Epirubicin 60 mg/m2 - IV - Days 1 and 8 - 5 Fluorouracil: 500mg/m2 - IV - Days 1 and 8 + Continuous Antibiotic Prophylaxis with Cotrimoxazole 960 mg (i.e.2x480 mg tablets) po-bid or Ciprofloxacin 500 mg - po-bid
- Arm 2: EC/T (Type: ACTIVE_COMPARATOR): 6 cycles - q 14 days (3 months) - Epirubicin 120 mg/m2 - IV - Day 1 - Cyclophosphamide 830 mg/m2 - IV - Day 1 - Filgrastim 5μg/kg/d - SC - Days 2 - 13 + Epoetin Alfa 40,000 IU - SC - once weekly (to begin within 1 week after start of protocol therapy as needed) 21 days from last administration of EC (EC/T) 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 - 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion
- Arm 3: AC/T (Type: ACTIVE_COMPARATOR): 4 cycles - q 21 days (3 months) - Adriamycin 60 mg/m2 - IV - Day 1 - Cyclophosphamide 600 mg/m2 - IV - Day 1 21 days from last administration of AC 4 cycles - q 21 days (3 months) - Paclitaxel 175 mg/m2 IV 3 hour infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).